Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial.
Hepatology research : the official journal of the Japan Society of Hepatology(2023)
摘要
This novel therapeutic vaccine was safe as perioperative immunotherapy for patients with HCC, and has the potential to strongly induce CD8 T cells infiltration into tumors.
更多查看译文
关键词
hLAG-3Ig plus poly-ICLC,hepatocellular carcinoma,peptide vaccination therapy,tumor immunogenicity
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要